华源制药与丰原集团围绕江山制药控制权斗争的案例研究
案例编号：
CN_2016KJYGSCW_3937
被浏览次数：
4019
案例名称：
华源制药与丰原集团围绕江山制药控制权斗争的案例研究
译名：
Consolidated Financial Statements and M&A——A Case Study on the Role of Controlling Right in an Unlisted Company
案例作者：
周华、莫彩华、吴晶晶、张姗姗
作者单位：
中国人民大学
译者：
-
案例企业：
上海华源制药股份有限公司、安徽丰原集团有限公司
行业：
生物制药
学科领域：
会计与公司财务、其他
规模：
大型
案例语种：
中文
案例类型：
描述型
中文关键词：
企业集团；合并报表；合并范围；控制
英文关键词：
Enterprise Group; Consolidated Financial Statements; Scope of Consolidation; Control
中文摘要：
上世纪90年代起，我国企业并购重组活动日趋活跃，企业并购领域新状况、新问题层出不穷。采用债务重组、关联交易等活动操纵报表数据的“报表式重组”现象并不鲜见，成为理论界和实务界热议的话题。自1902年美国钢铁公司的合并报表引发举世关注以来，合并报表历经百年仍未形成稳定合理的报表编报规则，也未形成公认的合并范围界定标准。合并报表规则的诸多缺陷是报表式重组乱象的温床，给企业管理层在短期内调节资产规模和财务业绩提供了便利。有“中国第一并购战”之称的华源制药和丰原集团争夺江山制药控制权的案例就是典型代表。本案例基于对现行会计准则的梳理和剖析，反思合并报表制度安排对企业并购行为的实际影响，以期为完善现行制度提供参考建议。
英文摘要：
Mergers and Acquisitions (M & A) have been increasingly popular since the 1990s in China, which leads to a variety of disputes and problems. Companies manipulate accounting numbers through artificial arrangements such as debt restructures, disposal of poor-quality assets with high price or transactions with related party. Nowadays both academics and practitioners attach importance to this issue. Even though the consolidated statement emerged early in U.S. in 1902, consensus on consolidation scope and process has not been reached so far. As a result, the M & A and consolidated statement are abused by management to manipulate financial performance. A typical case is the fight between Huayuan Pharmaceutical Group and Fengyuan Group for the control rights of JiangShan Pharmaceutical Ltd., which is also known as \"China\'s first takeover\". This case analyzes the existing accounting standards of consolidation and reveal the profoundly negative impacts of the consolidated statements in practice so as to provide some advice and references for further improvement of related accounting standards.
适用对象：
本科、学术硕士、专业硕士、高管培训
编写方式：
采编
开发时间：
2016
入库时间：
2016
索要案例使用说明：
确认订购本案例：
